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Abstract 23 
Autophagy is an important cellular degradation pathway with a central role in 24 
metabolism as well as basic quality control, two processes inextricably linked to aging. 25 
A decrease in autophagy is associated with increasing age, yet it is unknown if this is 26 
causal in the aging process, and whether autophagy restoration can counteract these 27 
aging effects. Here we demonstrate that systemic autophagy inhibition induces the 28 
premature acquisition of age-associated phenotypes and pathologies in mammals. 29 
Remarkably, autophagy restoration provides a near complete recovery of morbidity 30 
and a significant extension of lifespan, however, at the molecular level this rescue 31 
appears incomplete. Importantly autophagy-restored mice still succumb earlier due to 32 
an increase in spontaneous tumor formation. Thus our data suggest that chronic 33 
autophagy inhibition confers an irreversible increase in cancer risk and uncovers a 34 
biphasic role of autophagy in cancer development being both tumor suppressive and 35 
oncogenic, sequentially.   36 
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Main Text 37 
Physiological aging is a complex and multifaceted process associated with the 38 
development of a wide array of degenerative disease states. While there is no 39 
accepted singular underlying mechanism of aging, a combination of genetic, 40 
environmental and metabolic factors have been shown to alter the aging process1-3. 41 
As such, lifestyle and pharmacological regimens have been proposed that may offer 42 
health- and or life-span benefits4-6. However, despite chronological aging representing 43 
the greatest risk factor for pathological conditions as diverse as neurodegeneration, 44 
cancer, and cardiovascular disease, there is a paucity of genetic mammalian models 45 
that allow for dynamic modulation of key processes in mammalian aging.   46 
 47 
Autophagy is an evolutionarily conserved bulk cellular degradation system that 48 
functions to breakdown and recycle a wide array of cytoplasmic components from 49 
lipids, proteins and inclusion bodies, to whole organelles (e.g. mitochondria). 50 
Importantly a reduction in autophagic flux (the rate at which autophagosomes form and 51 
breakdown cellular contents) is associated with increasing age in mammals7. Evidence 52 
from lower organisms suggests that autophagy inhibition can negate the positive-53 
effects of regimens that extend lifespan, such as calorie restriction, rapamycin 54 
supplementation, and mutations in insulin signalling pathways 8-10. 55 
 56 
In mice, the constitutive promotion of autophagy throughout lifetime has been shown 57 
to extend health- and life-span in mammalian models11,12. These studies have provided 58 
hitherto missing evidence that autophagic flux can impact on mammalian longevity and 59 
supports the notion that the pharmacological promotion of autophagy may extend 60 
health-, and potentially life-span, in humans. However, whether a reduction in 61 
autophagy is sufficient to induce phenotypes associated with aging, and whether these 62 
effects can be reversed by restoring autophagy has to date not been addressed. 63 
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Considering that the therapeutic window for pharmacological intervention to counteract 64 
aging, and age-related diseases, will be later in life (as opposed to from conception), 65 
after autophagic flux has declined, it is critical to understand how the temporal 66 
modulation (inhibition and restoration) of autophagy may impact on longevity and 67 
health.  68 
 69 
To address these questions, we use two doxycycline (dox) inducible shRNA mouse 70 
models that target the essential autophagy gene Atg5 (Atg5i mice) to demonstrate that 71 
autophagy inhibition in young adult mice is able to drive the development of aging-like 72 
phenotypes and reduce longevity. Importantly we confirm that the restoration of 73 
autophagy is associated with a substantial restoration of health- and life-span, however 74 
this recovery is incomplete. Notably the degree of recovery is segmental, being 75 
dependent on both the tissue and metric analysed. A striking consequence of this 76 
incomplete restoration is that autophagy restored mice succumb to spontaneous tumor 77 
formation earlier and at an increased frequency than control mice, a phenotype not 78 
observed during autophagy inhibition alone. As such our studies indicate that despite 79 
the significant benefit, autophagy reactivation may also promote tumorigenesis in 80 
advanced ageing context.  81 
 82 
Reduced lifespan in Atg5i mice 83 
Previously, we have reported the development of a highly efficient dox inducible 84 
shRNA mouse model targeting Atg5 (Atg5i) 13 that phenocopies tissue-specific Atg5 85 
knockout (KO) mice. These mice lack brain expression of the shRNA and as such do 86 
not suffer from the lethal neurotoxic effects that characterise systemic autophagy 87 
knockout mice14,15, and enable us to perform longitudinal studies that were previously 88 
unachievable in vivo.  89 
 90 
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A common caveat of many mouse models is that genetic manipulations are often 91 
present during embryogenesis. Thus, any phenotypes that manifest are a combination 92 
of both developmental and tissue homeostasis effects. To avoid the generation of 93 
these compound effects, Atg5i mice were aged until eight-weeks (young adults) before 94 
being transferred to a dox-containing diet and followed to assess overall survival. Atg5i 95 
mice on long-term dox (LT-Atg5i) had a median survival of ~six months on dox (Male 96 
185 days; Female 207 days on dox) with no apparent sex bias (Fig. 1a-c and 97 
Supplementary Fig. 1a).  98 
 99 
In comparison to littermate controls, LT-Atg5i mice experienced a progressive 100 
deterioration, initially presenting with a reduction in coat condition within the first few 101 
weeks and a reduction in weight gain that became more pronounced over the life of 102 
the animal (Fig. 1d, e and Supplementary Fig. 1b). The majority of mice eventually 103 
succumbed to a general morbidity characterised by lethargy, piloerection, and a 104 
decrease in body condition, wherein they have to be sacrificed. As previously 105 
described with naturally aged colonies16, LT-Atg5i mice also appeared susceptible to 106 
eye infections and ulcerative dermatitis, the later being primarily localised to the ears 107 
and neck and ranging from mild to severe (Fig. 1f and Supplementary Fig. 1c, 108 
respectively).  109 
 110 
A singular cause of death in LT-Atg5i mice is difficult to determine and it is most likely 111 
of multifactorial aetiology across the cohort. At necropsy, all mice displayed 112 
hepatomegaly and splenomegaly in comparison to age and sex matched controls, 113 
consistent with phenotypes associated with tissue specific knockout mice17-19. Elevated 114 
serum ALT and reduced levels of serum albumin were present throughout dox 115 
administration of Atg5i mice, yet were altered further at the time of death only in a 116 
subset of samples (Supplementary Fig. 1f, g, yellow circles). Consistent with this, an 117 
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increase in serum bilirubin levels was only observed at the time of death within this 118 
same subset of mice (Supplementary Fig. 1h, yellow circle). These data suggest that 119 
severe liver failure occurs in only a fraction. 120 
 121 
Interestingly serum creatinine levels, a marker of kidney function, also displayed an 122 
increase only in a different subset of LT-Atg5i mice at the time of death, although they 123 
were not generally high during dox administration (Supplementary Fig. 2a). Loss of 124 
autophagy also correlated with a general thickening of the basement membrane and 125 
the presence of sclerotic (Supplementary Fig. 2b) and enlarged glomeruli 126 
(Supplementary Fig. 2c, d) in comparison to age-matched tissue samples, indicative 127 
of degenerative kidney disorder. LT-Atg5i mice also stained positively for the build-up 128 
of toxic amyloid proteins and the autophagy adaptor protein p62/Sqstm1, a condition 129 
normally associated with advancing age in humans (Supplementary Fig. 2e, f). These 130 
data suggest that, similar to the liver, systemic autophagy defect causes age-related 131 
degenerative alterations in kidney, yet only a distinct subset progresses to renal failure 132 
on death. In addition to this stochastic development of organ failure, LT-Atg5i mice 133 
universally presented with cardiomyopathy (Supplementary Fig. 2g). Histological 134 
examination highlighted the presence of enlarged, degenerate and vacuolated 135 
cardiomyocytes, in addition to the presence of cardiac fibrosis (Fig. 1g). 136 
 137 
Together, our data suggest that, despite the stereotypic premature death, LT-Atg5i 138 
mice suffered from a heterogeneous set of tissue degenerative disorders that appear 139 
to have contributed to an increase in mortality. Of note, there was no evidence of overt 140 
tumor development in these mice. 141 
 142 
Autophagy inhibition is associated with accelerated aging  143 
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All LT-Atg5i mice displayed evidence of kyphosis after four months of dox treatment 144 
that became progressively more pronounced as the animals aged until death, whilst 145 
16/28 LT-Atg5i mice displayed evidence of premature greying to varying degrees (Fig. 146 
1h). Furthermore LT-Atg5i mice displayed evidence of extramedullary hematopoiesis 147 
(Fig. 2a) and immune aggregations, commonly seen in aged mouse colonies, were 148 
also found in the liver, lungs and kidneys but were generally absent in age matched 149 
controls, although incidence of these increased in frequency with increasing age 150 
(Supplementary Fig. 3a).  151 
 152 
As previously described in hematopoietic Atg5 KO mice, LT-Atg5i mice also displayed 153 
an increase in cellularity of the peripheral immune system  18,20 (Supplementary Fig. 3b) 154 
with a myeloid skewing (Fig. 2b) reminiscent of age-associated chronic inflammation. 155 
This ‘inflamm-aging’ phenotype was further supported by an increase in serum TNF 156 
and IL-6 in LT-Atg5i mice in comparison to control (Fig. 2c).  157 
 158 
Skeletal muscle exhibits an age-related decline and autophagy has been reported to 159 
be required for the maintenance of Pax7 positive satellite cells (myogenic precursors) 160 
21. In accordance, LT-Atg5i mice displayed evidence of skeletal muscle degeneration 161 
with the presence of smaller fibres, a reduction in the population of Pax7 positive 162 
satellite cells, and an increase in central nucleation in comparison to age-matched 163 
littermate control mice (Fig. 2d-g). Central nucleation represents muscle fibre 164 
regeneration after acute muscle injury but an increase in basal frequency of centrally 165 
nucleated myofibres is also a sign of sarcopenia at geriatric age both in mice and 166 
human 22. Additionally, LT-Atg5i muscle fibres displayed increased staining positivity 167 
for the mitochondrial marker TOM20 indicative of increased mitochondrial mass and a 168 
reduction in autophagy mediated turnover (Fig. 2h).  169 
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 170 
The accumulation of senescent cells is considered a key marker of chronological 171 
aging. Autophagy has been reported to have context dependent and sometimes 172 
opposing roles during cellular senescence: typically basal autophagy is considered to 173 
promote fitness and its loss may promote senescence, whereas in oncogene-induced 174 
senescence, autophagy may be important for the establishment of senescent 175 
phenotypes 23-26. To determine if the systemic loss of basal autophagy is sufficient to 176 
drive the establishment of cellular senescence in vivo we performed western blotting 177 
across a number of tissues from 4-month dox treated LT-Atg5i mice and found an 178 
increased staining pattern for key senescence markers (i.e. p16, p21, and p53) (Fig. 179 
3a-c and Supplementary Fig. 3c). Additionally, whole mount senescence-associated 180 
beta-galactosidase staining from 6-month treated livers highlighted a marked increase 181 
in staining patterns in comparison to LT-Control mice (Fig. 3d). Histologically, nuclear 182 
accumulation of p21 was also evident, particularly in hepatocytes with enlarged 183 
morphology (Fig. 3d). Furthermore LT-Atg5i mice display a significant increase in both 184 
the abundance and frequency of telomere-associated γ-H2AX foci (TAF), which have 185 
been shown to correlate with senescence, increasing age and mitochondrial 186 
dysfunction (Fig. 3e, f) 27-29. These data reinforce the age acceleration upon systemic 187 
autophagy reduction. 188 
 189 
Of note, similar gross phenotypic results were also seen in mice with a second hairpin 190 
targeting Atg5 (LT-Atg5i_2). LT-Atg5i_2 mice display evidence of premature aging-like 191 
phenotypes (Supplementary Fig. 4a-c), however the appearance of these phenotypes 192 
is delayed in comparison to LT-Atg5i mice, seemingly due to a hypomorphic reduction 193 
in Atg5. Accordingly, these mice displayed the accumulation of p62/Sqstm1 and LC3 194 
in multiple tissues but at lower levels in comparison to LT-Atg5i mice, and did not 195 
display phenotypes associated with complete Atg5 knockout mice, including 196 
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hepatomegaly and splenomegaly (Supplementary Fig. 4d-f). These findings in 197 
particular are important as they establish that the reduction in longevity and presence 198 
of aging phenotypes is not dependent on the hepatomegaly and splenomegaly 199 
phenotypes encountered in the original LT-Atg5i mouse strain with the highest degree 200 
of autophagy inhibition. 201 
  202 
Combined these data support a role for basal autophagy in maintaining tissue and 203 
organismal homeostasis and provide evidence that causally links autophagy inhibition 204 
to the induction of aging-like phenotypes in mammals. 205 
 206 
Autophagy Restoration Partially Reverses Accelerated Aging-like Phenotypes 207 
We next sought to determine whether autophagy restoration alone is able to reverse 208 
the aging-like phenotypes by removing dox from the diet. Eight-week old Atg5i and 209 
control mice treated with dox for four months, the point at which they universally 210 
presented with kyphosis, were switched back to a diet absent of dox leading to a 211 
restoration in Atg5 levels and autophagy (termed R-Atg5i cohort) 13. Interestingly the 212 
senescence marker p21 remained elevated across a number of tissues 2 months post 213 
dox removal (Fig. 4a, b).  214 
 215 
An increase in chronological age is generally associated with the deviations in multiple 216 
health parameters that when measured can be combined into a clinical ‘frailty-score’ 217 
30. As expected R-Atg5i mice displayed an initial increase in their frailty scores during 218 
autophagy inhibition in comparison to littermate controls, yet once mice have been 219 
switched back to a diet absent of dox, the frailty scores displayed a significant decrease 220 
over the next four months (Fig. 4c, Supplementary Movie. 1). In contrast, LT-Atg5i mice 221 
treated on dox for 6 months (median survival is around ~6 months on dox) continued 222 
to display a significant difference in their frailty scores, while almost all LT-Atg5i mice 223 
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had already succumbed by eight-months (Fig. 4c). A similar increase in frailty was also 224 
noted in the LT-Atg5i_2 cohorts (Supplementary Fig. 4b). The penetrant kyphosis 225 
phenotype was largely irreversible, however 3/26 R-Atg5i mice did show evidence of 226 
recovery from kyphosis, while no mice displayed a reversal of the greying phenotypes. 227 
As such, while autophagy inhibition in vivo appears to promote frailty, autophagy 228 
restoration is seemingly able to substantially reverse this effect. 229 
 230 
Remarkably the profound immune-associated phenotypes that we observed in 231 
autophagy-deficient LT-Atg5i mice were reversed in R-Atg5i mice. Serum markers of 232 
inflammation and WBC counts were indistinguishable between R-Atg5i and R-Control 233 
mice (Fig. 4d, e and Supplementary Fig. 5a). However, it should be noted that there 234 
was a trend towards a larger red blood cell distribution width (RDW) in aged R-Atg5i 235 
mice removed from dox for 8 months (14 months old), which has previously been linked 236 
to a range of diseases and an increased risk of acute myeloid leukemia (AML) (Fig. 4f) 237 
31. Additionally, R-Atg5i livers displayed a complete reversal of hepatomegaly and 238 
serum ALT levels (Supplementary Fig. 5c and c). The kidneys of R-Atg5i mice 239 
appeared to recover from autophagy inhibition and lacked evidence of sclerotic and 240 
enlarged glomeruli (Supplementary Fig. 5 d-f). Consistently, serum albumin levels 241 
displayed evidence of normalisation, although there was still a trend for reduced levels 242 
in R-Atg5i mice at the time point tested, suggesting that liver and/or kidney functions 243 
are largely recovered, if not completely (Supplementary Fig. 5g). 244 
 245 
Similarly, the protein aggregation marker p62/SQSTM1 in the liver appeared much 246 
reduced in R-Atg5i mice in comparison to the LT-Atg5i mice, yet a small but substantial 247 
number of cells still exhibited a marked accumulation of p62 aggregation in R-Atg5i 248 
mice that had been off dox for four months (Fig. 5a). Additionally, R-Atg5i livers were 249 
also found to contain the presence of ceroid-laden macrophages and lipofuscin 250 
positivity, pigments known to increase with age and not seen in age-matched controls 251 
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mice (Fig. 5b). Importantly, and in accordance with this partial restoration phenotype, 252 
molecular markers of aging such as TAF also remained significantly elevated in R-253 
Atg5i mice. This is consistent with the persistent nature of telomeric DNA damage, 254 
which is reported to be irreparable27,32. Together with other senescence markers (Fig. 255 
4b), these data suggest that a portion of the cellular damage caused by a chronic block 256 
in autophagy is irreversible (Fig. 5c).  257 
 258 
Morphological analysis of skeletal muscle from R-Atg5i mice with autophagy restored 259 
suggests that muscle fibre size and morphology display no sign of recovery at the 260 
timepoint analysed (Fig. 5d, e and Supplementary Fig. 6a, b). However central 261 
nucleation and satellite cell frequency appeared to display a heterogeneous pattern, 262 
with evidence of recovery apparent in some individuals (Fig. 5f, g). As expected with 263 
Atg5 restoration, mitochondrial levels as determined by Tom20 positivity were restored 264 
to control levels (Fig. 5h). Additionally, the cardiac fibrosis observed LT-Atg5i mice 265 
appears to still be present four months post dox removal in R-Atg5i cohorts 266 
(Supplementary Fig. 6c). Together these data suggest that autophagy restoration may 267 
have tissue and pathology specific limitations in the capacity to recover from the tissue 268 
and cellular damage induced upon its inhibition. Crucially, whilst some tissues, such 269 
as the liver, appear to recover, they are still associated with age-associated 270 
pathologies at the molecular level. 271 
 272 
Accelerated tumor development in R-Atg5i mice 273 
As R-Atg5i mice displayed some evidence of organismal rejuvenation and an increase 274 
in overall health, we sought to determine if autophagy restoration is able to reinstate 275 
natural longevity to the level seen in littermate control mice, or whether the damage 276 
accumulation impacting on lifespan was irreversible. Remarkably, while the life-span 277 
of R-Atg5i mice was significantly extended in comparison to LT-Atg5i mice (median 278 
survival 493 days versus 185 days since treatment began, respectively), it was also 279 
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significantly shorter than the R-Control cohorts (Fig. 6a). In marked contrast to LT-280 
Atg5i mice, the cause of death was predominantly associated with the development of 281 
tumors with an increased frequency and at earlier timepoints (Fig. 6b-d). Of note a 282 
whole-body mosaic Atg5 knockout mouse model has been previously reported to only 283 
develop liver adenomas but without any malignant tumors33. Together, our data 284 
suggest that a temporary period of autophagy inhibition may be enough to induce 285 
irreversible cellular damage, which might facilitate tumor development cooperatively 286 
with the restoration of autophagy. 287 
 288 
Discussion 289 
While the rate of autophagic flux is believed to decrease with advancing age and has 290 
been postulated to be a driver of aging in multicellular organisms, evidence in 291 
mammals has been limited to the role of autophagy in maintaining stem cell 292 
populations18,21. Such systemic organismal studies have been impossible to conduct 293 
owing to the embryonic or neonatal lethality, and rapid neurotoxicity in adult mice, that 294 
accompanies systemic autophagy ablation14,34. The temporal control and lack of brain 295 
shRNA expression afforded by the Atg5i model have enabled us to circumvent these 296 
barriers, and separate developmental from tissue homeostatic effects that cannot be 297 
distinguished in aging models based on constitutive or in utero genetic modifications. 298 
Our findings support the theory that a reduction in autophagy is sufficient to induce 299 
several molecular and phenotypic characteristics associated with mammalian aging, 300 
including the development of age-associated diseases and a reduction in longevity. 301 
Here it is notable that our Atg5i mice phenocopy other models of aging driven by the 302 
accumulation of damage and in particular mitochondrial dysfunction35,36. 303 
  304 
Several health and life-span extending regimens in mammals, such as calorie 305 
restriction or pharmacological modulation, have been posited to exert their effects 306 
through the regulation of autophagy7,37. However, these effects are also pleiotropic in 307 
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nature and alter a multitude of cellular processes, making it impossible to deconvolute 308 
and ascribe the role of autophagy in these settings. Whilst recent genetic models that 309 
promote autophagic flux continuously throughout life have demonstrated an extension 310 
of health- and life-span in mammalian systems11,12, it is unclear if the damage 311 
established by a loss of autophagy is sufficient for age acceleration and can be 312 
reversed. If therapeutic regimens in humans are to be established later in life, once 313 
autophagy-associated damage has accumulated, ascertaining the capacity for 314 
autophagy restoration to repair this damage is critical. In our model, systemic 315 
inflammation and frailty scores displayed a marked improvement upon autophagy 316 
restoration, which resulted in increased survival. However, while some tissues (i.e. 317 
liver and heart) displayed macroscopic normalisation, further analysis highlighted the 318 
persistence of pathological phenotypes. Our results indicate that the reversibility of 319 
markers of aging such as TAF, or macroscopic phenotypes such as greying and 320 
kyphosis may not recover. It should also be noted that we have chosen a late time-321 
point to restore autophagy as this provided a clear and ubiquitous distinction between 322 
control and autophagy inhibited mice, shorter time points or intermittent dosing 323 
regimens may display further heterogeneity in damage and recovery phenotypes. 324 
 325 
Our unexpected finding, that the temporal inhibition of autophagy predisposes to 326 
increased tumor development, provides a potential genetic explanation for the context-327 
dependent role of autophagy in tumorigenesis38,39: i.e. autophagy can be a tumor 328 
suppressor33,40,41 or a tumor promoter42-44. The irreversible damage induced by 329 
autophagy inhibition (e.g. genomic instability), might confer tumor susceptibility, while 330 
autophagy activity is perhaps required for actual malignant transformation. The clinical 331 
implication of our data is not limited to the advanced age state. As some 332 
pathophysiological states, such as obesity, are associated with an insufficient level of 333 
autophagy45, it would be interesting to determine if obese individuals retain an 334 
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increased risk of tumor development even upon weight loss, in comparison to never 335 
obese populations. 336 
  337 
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Methods 462 
Atg5i mouse maintenance and aging: The generation and initial characterization of 463 
the Atg5i transgenic line has previously been described in detail13. Mice were 464 
maintained on a mixed C57Bl/6 X 129 background with littermate controls used in all 465 
experiments. All experimental mice were maintained as heterozygous for both the 466 
shRNA allele and CAG-rtTA3 alleles, whereas control littermates were lacking one of 467 
the alleles. Guide sequences were as follows: Atg5i TATGAAGAAAGTTATCTGGGTA 468 
13; Atg5i_2 TTATTTAAAAATCTCTCACTGT. Mice were maintained in a specific 469 
pathogen-free environment under a 12-h light/dark cycle, having free access to food 470 
and water. These mice were fed either a laboratory diet (PicoLab Mouse Diet 20, 5R58) 471 
or the same diet containing doxycycline at 200 ppm (PicoLab Mouse Diet, 5A5X). For 472 
this study mice were aged for two months before doxycycline administration in the diet. 473 
Mice were enrolled either to time-point study groups or long-term longevity cohorts 474 
(LT- and R- groups). Experienced animal technicians checked mice daily in a blinded 475 
fashion, and additionally mice were weighed and hand-checked on a weekly basis. 476 
Mice found to be of deteriorating health were culled under the advice of senior animal 477 
technicians if displaying end of life criteria. These signs include a combination of (1) 478 
hunched body position with matted fur, (2) piloerection, (3) poor body condition (BC) 479 
score (BC1 to 2), (4) failure to eat or drink, (5) cold to touch, and or (6) reduced mobility, 480 
including severe balance disturbances and ataxia. In accordance with UK home office 481 
regulations any mice suffering a 15% loss of body weight were also considered to be 482 
at an end-point. Note that for LT- longevity cohorts a portion of control mice were culled 483 
to generate age-matched littermate control tissue. These mice are marked as 484 
censored events on the survival curve. For analysis mice were treated as alive up to 485 
the point of their removal from the study where they are considered lost to follow-up 486 
and are not included in the calculations of median longevity. All experiments were 487 
performed in accordance with national and institutional guidelines, and the ethics 488 
review committee of the University of Cambridge approved this study.  489 
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 490 
Frailty Scoring: Clinical frailty scoring was determined using the previously published 491 
frailty index30. A blinded researcher and animal technician performed all frailty scores 492 
independently within the same 48 hr period and scores were compared afterwards to 493 
ensure accuracy of phenotype scoring. 494 
 495 
Pathology and Immunohistochemistry: Explanted tissues were fixed in 10% 496 
neutral-buffered formalin solution for 24 hr and transferred to 70% ethanol. Tissues 497 
were embedded in paraffin, cut in 3μm sections on poly-lysine coated slides, 498 
deparaffinized, rehydrated, and stained with H&E. The PAS, Congo Red and Massons 499 
Trichrome histochemical stains were performed according to established protocols.  500 
An experienced pathologist reviewed all histology blinded for evidence of tumors and 501 
tissue pathologies. For immunohistochemistry and tissue immunoflourescence 502 
formalin-fixed paraffin-embedded samples were de-waxed and rehydrated. For anti-503 
P21 (Santa Cruz, SC-6246; 1:500), and anti-TOM20 (Santa Cruz SC-11415, 1:500) 504 
staining antigen unmasking was performed with citrate buffer (10 mM sodium citrate, 505 
0.05% Tween 20, pH 6) in a pressure cooker for 5 min at 120°C. For P21 exogenous 506 
peroxidases were quenched in 3% H2O2/PBS for 15 min and the remaining steps were 507 
performed according to Vector Labs Mouse on Mouse staining kit (MP-2400). The 508 
remaining antibodies were used at the following concentrations and ran on the Leica 509 
Polymer Detection system (DS9800) with the Leica automated Bond platform: Anti-510 
SQSTM1 (Enzo, BML-PW9860; 1:750), anti-KI67 (Bathyl Laboratories, IHC-00375; 511 
1:1000), Anti-LC3 (Nanotools, LC3-5F10 0231-100, 1:400).  512 
 513 
For TOM20 analysis the intensity of signal per entire muscle section was determined 514 
and an average measurement of intensity per unit area calculated. Samples were then 515 
plotted as a fold increase relative to the average intensity per unit of control muscle 516 
sections  517 
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 518 
For kidney glomeruli size tissue sections were analysed using ImageScopeTM (Leica 519 
Biosystems) and the cross-sectional area of ten glomeruli in the renal cortex was 520 
reported per sample.  521 
 522 
Western Blotting: Western blot analysis was performed as previously23. Tissue 523 
samples were homogenized with the Precellys 24 tissue homogenizer in laemmeli 524 
buffer and samples ran on 12.5% or 15% gels. Protein was transferred to PVDF 525 
membranes (Immobilon, Millipore), which was subsequently blocked for 1 hr at room 526 
temperature (5% milk solution in TBS-Tween 0.1%) before incubating with primary 527 
antibody at 4oC overnight. An appropriate HRP-conjugated secondary antibody was 528 
incubated at room temperature for 1 hr. Western blots were visualized with 529 
chemiluminsence reagents (Sigma, RPN2106). Antibodies were used at the following 530 
concentrations: Anti-ATG5 (Abcam, ab108327; 1:1000), anti-LC3 (Abcam, ab192890; 531 
1:1000), anti-ACTIN (Santa Cruz Biotechnology, I-19; 1:5000 [no longer commercially 532 
available]), anti-P53 (Cell Signalling Technologies, Clone 1C12; 1:1000), anti-P21 533 
(Santa Cruz, SC-6246; 1:1000), anti-Histone H3 (Abcam, ab1791; 1:5000), anti-P16 534 
(Santa Cruz, SC-1207; 1:1000), anti-HMGA1 (Abcam, ab129153; 1:1000).  535 
 536 
Blood and serum analysis: Whole blood composition was performed using the 537 
Mythic Hematology Analyser to determine whole blood counts, immune composition, 538 
and RDW. Mouse cytokines were determined using a cytometric bead array (BD 539 
Biosciences, Catalogue number: 552364). Sera isolated from mice were analyzed by 540 
the Core Biochemical Assay Laboratory (CBAL), Cambridge, UK for Alanine 541 
Transferase (Siemens Healthcare), Albumin (Siemens Healthcare), Bilirubin (Siemens 542 
Healthcare), and Creatinine (Siemens Healthcare) using automated Siemens 543 
Dimension RxL and ExL analyzers. 544 
 545 
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Telomere Associated DNA Damage Foci (TAF) 546 
Formalin-fixed paraffin-embedded liver sections were hydrated by incubation in 100% 547 
Histoclear, 100, 95 and 2X 70% methanol for 5 min before washed in distilled water 548 
for 2X 5 min. For antigen retrieval, the slides were placed in 0.1 M citrate buffer and 549 
heated until boiling for 10 min. After cooling down to room temperature, the slides were 550 
washed 2X with distilled water for 5 min. After blocking in normal goat serum (1:60) in 551 
BSA/PBS, anti-γ-H2A.X primary antibody (Cell Signalling Technologies, S139; 1:250) 552 
was applied and incubated at 4 °C overnight. Slides were washed 3X in PBS, 553 
incubated with secondary antibody for 30 min, washed three times in PBS and 554 
incubated with Avidin DCS (1:500) for 20 min. Following incubation, slides were 555 
washed three times in PBS and dehydrated with 70, 90 and 100% ethanol for 3 min 556 
each. Sections were denatured for 5 min at 80 °C in hybridization buffer (70% 557 
formamide (Sigma), 25 mM MgCl2, 1 M Tris pH 7.2, 5% blocking reagent (Roche) 558 
containing 2.5 μg ml−1 Cy-3-labelled telomere specific (CCCTAA) peptide nuclei acid 559 
probe (Panagene), followed by hybridization for 2 h at room temperature in the dark. 560 
The slides were washed with 70% formamide in 2×SSC for 2X 15 min, followed by 561 
2×SSC and PBS washes for 10 min. Sections were incubated with DAPI, mounted and 562 
imaged. In depth Z stacking was used (a minimum of 40 optical slices with ×100 563 
objective) followed by Huygens (SVI) deconvolution. 564 
 565 
Senescence associated beta-galactosidase staining 566 
Whole tissue samples were washed in PBS (pH5.5) before being fixed in 0.5% 567 
Glutaraldehyde overnight and washed 2X 15 min in PBS (pH5.5) at 40C.  SA-β-gal 568 
activity was assessed after incubation in X-Gal solution for 90 minutes at 370C. 569 
   570 
Muscle Morphopmetric Analysis: Mice were sacrificed at the time points described 571 
and dissected muscle was rapidly frozen in liquid nitrogen cooled isopentane to 572 
maintain structure and minimize tissue artifacts. Experimental mice and age-matched 573 
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littermate controls were isolated at the same time to ensure processing was consistent 574 
between groups. Frozen muscles were equilibrated in a cryostat chamber to −20°C 575 
and cryosections 10-μm thick were then cut from the middle third of the sample and 576 
collected on poly-L-lysine (0.5 mg/ml)–coated glass slides. Sections were allowed to 577 
air dry and were then frozen at -80°C prior to use. Samples were brought to 4°C on ice 578 
and fixed in a 4% w/v 0.45 mm filtered paraformaldehyde solution in 1 x PBS for 15 579 
min at 4°C. PFA was removed by three 5 min washes in 1 x PBS, then blocked in 10% 580 
v/v serum in 1 x PBST (0.01% Tween-20) for 1 hr at RT. Primary anti-dystrophin 581 
antibody (Abcam, ab15277, 1:1000) was then applied in 1 x PBST containing 10% v/v 582 
serum for 2 h at room temperature. Three 5-min PBST washes were applied before 583 
secondary antibody conjugated to Alexa Fluor 647, with DAPI at 1:1000, incubation in 584 
PBST and 10% v/v serum for 1 h at room temperature. Sections were finally washed 585 
three times for 15 min before mounting in Vectorshield Antifade Mounting Medium 586 
(Vector Labs). Whole cross-sections of TA muscles were produced via montaged 40× 587 
magnification tile scans (Zeiss Axio Z1 Widefield system). Morphometric analysis was 588 
performed using Fiji open source software as previously described (26461208). 589 
Simultaneous DAPI nuclear stain was used for central nucleation count. PAX7 counts 590 
were performed manually in a blinded fashion, a satellite cell was defined as having a 591 
PAX7 positive nuclei within a LAMININ cell border staining. For immunostaining the 592 
following antibodies were used anti-PAX7 PAX7 (DSHB, PAX7, 1:50), after pre-593 
treatment with Vector Labs Mouse on Mouse Blocking Reagent (MKB-2213) according 594 
to manufacturer’s instructions and anti-LAMININ (Abcam, ab11576, 1:1000).   595 
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Figure Legends 596 
 597 
Figure 1: Autophagy inhibition decreases lifespan.  598 
a-c, LT-Atg5i mice on dox continuously from two months old display a reduced lifespan 599 
in comparison to LT-Control as shown in survival graphs for (a) combined (p<0.0001), 600 
(b) male (p<0.0001), (c) female (p<0.0001) (Mantel-Cox test). Median survival (days 601 
on dox) and mice per group are indicated. d-e, During this period LT-Atg5i mice also 602 
display a reduced weight gain in both (d) male and (e) female cohorts. f, LT-Atg5i mice 603 
also display an increased frequency of skin inflammation and eye infections in 604 
comparison to age-matched LT-Control mice. g, Cardiac fibrosis was also evident in 605 
LT-Atg5i mice. Representative images of H&E and Massons Trichrome are shown. 606 
Scale bars,100 μm. h, Age-matched skinned mice. LT-Atg5i mice show kyphosis 607 
(yellow dotted line traces the arch of the spine). They often displayed premature 608 
greying (dotted rectangle). Arrows indicate the presence of inflammation.  609 
 610 
Figure 2:  LT-Atg5i mice present with accelerated aging phenotypes. 611 
a, Extramedullary haematopoiesis is present in the spleens of LT-Atg5i mice in 612 
comparison to age-matched controls. Scale bars,100 μm. b, Composition of the 613 
peripheral immune system in LT-Atg5i mice is reminiscent of old control mice. (n=5-6 614 
mice per group). c, Six-month-old LT-Atg5i mice (four months dox treatment) displayed 615 
increased serum levels of IL-6 and TNF (LT-Atg5i n=5, LT-Ctrl n=8; Mann Whitney 616 
Test). d-h, LT-Atg5i mice display alterations in skeletal muscle after six-months of dox 617 
treatment. (d) LT-Atg5i mice display a significant difference in minimum feret size (n= 618 
4 R-Ctrl and 4 R-Atg5i, Mann Whitney test) and (e) cross-sectional area (n= 4 R-Ctrl 619 
and 4 R-Atg5i, Mann Whitney test). LT-Atg5i mice also display a decrease in Pax7 620 
nuclear positivity per fibre (f), an increase in central nucleation (g), and positivity for 621 
the mitochondrial marker TOM20 (h), as determined by tissue immunofluorescence 622 
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(unpaired two-tailed Welches t-test; n= 4 R-Ctrl and 4 R-Atg5i). Error bars indicate 623 
standard deviations. *p<0.05; **p<0.01, ***p<0.001 624 
 625 
Figure 3:  Autophagy inhibition drives senescence in vivo 626 
a-d, Markers of senescence can also be seen across multiple tissues in our LT-Atg5i 627 
cohorts treated with dox for four months including in (a) kidney, (b) heart, and (c) liver. 628 
(d) LT-Atg5i livers stain positively for senescence associated β-galactosidase and p21 629 
unlike age-matched control mice (scale bar, 25 μm). e, Six-month doxycycline treated 630 
LT-Atg5i livers display an increase in the frequency and abundance of γ-H2AX at 631 
telomeres, a marker associated with increasing chronological age (unpaired two-tailed 632 
t-test; n=5). f, A representative example image shown. Arrowheads point to TAF that 633 
are magnified on the right of the image. Scale bar, 10 μm. Error bars indicate standard 634 
deviation ***p<0.001 635 
 636 
Figure 4:  Restoration of autophagy partially restores health-span 637 
a, Schematic of R-Atg5i study. Briefly two-month old mice are given dox to induce Atg5 638 
downregulation for four months at which point they exhibit ageing-like phenotypes. Dox 639 
is then removed and autophagy restored. b, Tissues from R-Atg5i mice with autophagy 640 
restored for two months display evidence of ATG5 protein and autophagy restoration, 641 
yet still stain positively for markers of senescence. c, Atg5i mice on dox for four months 642 
and six months display increase frailty scores in comparison to controls (ARU, arbitrary 643 
units). While R-Atg5i mice where autophagy has been restored for four months, display 644 
a recovery (Two-way ANOVA with Tukey’s correction for all comparisons, n=3-16). d, 645 
Whole blood cell counts from R-Atg5i mice display no difference in comparison to age 646 
matched R-Control mice (unpaired two-tailed t-test; n=11 per group). e, Inflammatory 647 
serum cytokines IL6 and TNF are equivalent in R-Atg5i and R-Control mice two-648 
months post dox removal (Mann Whitney test; n= 3 R-Ctrl and 4 R-Atg5i). f, Red blood 649 
cell distribution width (RDW) is altered in aged autophagy-restored cohorts (four 650 
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months dox, eight months restoration) (unpaired two-tailed t-test; n=14 per group). 651 
Error bars indicate standard deviation; NS denotes not significant. *p<0.05; **p<0.01, 652 
***p<0.001. 653 
 654 
Figure 5:  Restoration of autophagy does not reverse markers of aging 655 
a, p62/Sqstm1 staining of R-Atg5i liver highlights the incomplete removal of 656 
aggregates four months after autophagy restoration. Scale bars,100 μm. b, The same 657 
livers have a higher incidence of age associated pigmentation in comparison to age-658 
matched control mice. (yellow arrow). c, TAF frequency and abundance also remains 659 
elevated in R-Atg5i mice (unpaired two-tailed t-test; n= 4 R-Ctrl and 3 R-Atg5i). d-h, 660 
Skeletal muscle analysis from four months dox treated and two months restored R-661 
Atg5i mice. R-Atg5i muscle fibres continue to display significant alterations in (d) 662 
minimum feret size (n= 4 R-Ctrl and 3 R-Atg5i, Mann Whitney test) and (e) cross-663 
sectional area (n= 4 R-Ctrl and 3 R-Atg5i, Mann Whitney test), but with a recovery of 664 
(f) central nucleation. (g) Pax7 nuclear positivity per fibre and (h) positivity for the 665 
mitochondrial marker TOM20 displays a heterogeneous recovery pattern in these 666 
mice, as measured by tissue immunofluorescence. (f-h, unpaired two-tailed Welches 667 
t-test; n= 2 R-Ctrl and 4 R-Atg5i). Error bars indicate standard deviations. *p<0.05; 668 
**p<0.01, ***p<0.001 669 
 670 
Figure 6:  R-Atg5i mice are associated with accelerated spontaneous tumor 671 
development 672 
a, R-Atg5i mice on display a reduced lifespan in comparison to R-Control mice 673 
(p<0.01). b, Increased frequency of spontaneous tumour formation in R-Atg5i cohorts 674 
(p<0.001). c, Tumor spectrum in R-Atg5i mice versus R-Control mice. d - e, 675 
Examples of R-Atg5i tumour histology. H&E staining and immunostaining of indicated 676 
proteins. Scale bars, 100μm. 677 
 678 
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Supplementary Figure 1: Characterisation of LT-Atg5i mice 679 
a, LT-Atg5i mice display no life-span associated sex bias (Red, LT-Atg5i Males; Purple, 680 
LT-Atg5i Females; p=0.8). b, LT-Atg5i mouse weight plateau while LT-Control mice 681 
continue to gain weight over their lifetime. c, Example of mouse suffering from 682 
ulcerative dermatitis. d, Splenic weights were increased in LT-Atg5i mice in 683 
comparison to age matched LT-Control mice. e, LT-Atg5i mice also display an increase 684 
in liver weight. f-h, liver function of LT-Atg5i mice as determined using serum samples. 685 
LT-Atg5i mice on dox for 4 months display (f) an increase in serum ALT and (g) a 686 
decrease in serum albumin that is further exacerbated in a subset of LT-Atg5i EoL 687 
individuals (yellow circles). (h) The only sample tested that displayed an increase in 688 
serum bilirubin levels was also from a mouse displaying high levels of serum ALT and 689 
low levels of serum album. Error bars indicate standard deviations. *p<0.05; **p<0.01, 690 
***p<0.001 691 
 692 
Supplementary Figure 2: Kidney alterations in LT-Atg5i mice 693 
(a) LT-cohorts treated with doxycycline for 6 months mice display no significant 694 
differences in serum creatinine levels (unpaired two-tailed Welches t-test, NS denotes 695 
not significant; n= 3 LT-Control and 4 LT-Atg5i). At death only a subset of LT-Atg5i 696 
mice display an increase in serum creatinine levels. b-f, LT-Atg5i mouse kidneys 697 
treated with doxycycline for 6 months present with (b) evidence of sclerotic glomeruli 698 
determined using PAS stain that are also (c-d) enlarged and hypercelluar in 699 
comparison to LT-Control (p=0.0479, unpaired two-tailed t-test; n= 4 LT-Control and 3 700 
LT-Atg5i, the cross-sectional area of 10 randomly chosen glomeruli were measured 701 
per mouse). (e) Congo red and (f) P62/Sqstm1 staining of LT-Atg5i mouse kidneys 702 
treated with doxycycline for 6 months highlights an increase in protein aggregation not 703 
present in age-matched LT-Control mice. g, Cardiac tissue from LT-Atg5i mice at death 704 
was significantly heavier than age-matched LT-Control mice. (p=0.0108). Error bars 705 
indicate standard deviations. *p<0.05; **p<0.01, ***p<0.001 706 
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/528984doi: bioRxiv preprint first posted online Jan. 23, 2019; 
 29 
 707 
Supplementary Figure 3: Systemic alterations in LT-Atg5i mice 708 
a, LT-Atg5i mice display evidence of widespread immune infiltration across multiple 709 
tissues in comparison to age-matched controls. Scale bars,100 μm. b, White blood cell 710 
counts (WBC) of LT-Control and LT-Atg5i mice treated with doxycycline for 4 months 711 
(6 months old) (unpaired two-tailed Welches t-test, n=5-6 per group). c, Skeletal 712 
muscle displays markers of senescence in LT-Atg5i cohorts on doxycycline for 4 713 
months. **p<0.01 714 
 715 
Supplementary Figure 4: Hypomorphic LT-Atg5i_2 mice also display aging 716 
phenotypes 717 
a-c, LT-Atg5i_2 mice phenotypically recapitulate premature ageing phenotypes 718 
including (a) kyphosis, (b) increased frailty (ARU, arbitrary units; Mann-whitney n= 14 719 
LT-Control and 5 LT-Atg5i_2 mice), and (c) reduced longevity. d-f However, Atg5i_2 720 
mice appear to have a hypomorphic phenotype and do not recapitulate the phenotypes 721 
found in Atg5 knock-out and LT-Atg5i. These include no evidence of (d) hepatomegaly 722 
or (e) splenomegaly. (f) Correspondingly, p62/SQSTM1 and LC3 levels do not 723 
accumulate to the same degree in LT-Atg5_2 mice treated with doxycycline for 6 724 
weeks. Scale bars,100 μm. Error bars indicate standard deviations. *p<0.05 725 
 726 
Supplementary Figure 5: Autophagy restoration reverses hepatomegaly and 727 
splenomegaly 728 
a, Splenic and b, liver weights from R-Atg5i mice exhibit evidence of recovery. c, In 729 
addition R-Atg5i mice display a reduction in serum ALT levels (unpaired two-tailed 730 
Welches t-test; n= 3-4 per cohort). d-f, R-Atg5i mice 4 months post dox removal display 731 
evidence of recovery in the kidneys as determined by (d-e) normalisation of glomeruli 732 
size appeared relative to age-matched controls (unpaired two-tailed Mann whitney, 733 
n=3-4 mice per group) and (f) the absence of sclerosis. g, A partial recovery in serum 734 
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albumin levels is also present in these mice unpaired two-tailed Welches t-test; n= 2-735 
9 per cohort). Error bars indicate standard deviations. *p<0.05; **p<0.01, ***p<0.001 736 
 737 
Supplementary Figure 6: Autophagy restoration displays segmental rescue of 738 
tissue phenotypes 739 
a-b, Skeletal muscle displays no rescue of phenotype once Atg5i mice are removed 740 
from dox. As determined by (a) minimal feret size, and (b) cross-sectional area. 741 
(unpaired two-tailed Welches t-test, n=3-5 per group). c, Cardiac fibrosis was still 742 
present in R-Atg5i mice 4 months post dox removal. Error bars indicate standard 743 
deviations. *p<0.05 744 
 745 
Supplementary Movie. 1: R-Atg5i mice 4 months post dox removal highlighting the 746 
stochastic response to autophagy restoration. All mice were treated on dox for 4 747 
months before dox removal for 2 months. At this stage, 100 % of mice show kyphosis. 748 
The movie represents three examples with different levels of recovery. Mouse I exhibits 749 
little recovery, whereas mouse III looks normal with no sign of kyphosis. Mouse II 750 
appears active but with mild kyphosis. 751 
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/528984doi: bioRxiv preprint first posted online Jan. 23, 2019; 
Figure 1: Autophagy inhibition decreases lifespan. 
a-c, LT-Atg5i mice on dox continuously from two months old display a reduced lifespan in compari-
son to LT-Control as shown in survival graphs for (a) combined (p<0.0001), (b) male (p<0.0001), (c) 
female (p<0.0001) (Mantel-Cox test). Median survival (days on dox) and mice per group are indicated. 
d-e, During this period LT-Atg5i mice also display a reduced weight gain in both (d) male and (e) 
female cohorts. f, LT-Atg5i mice also display an increased frequency of skin inflammation and eye 
infections in comparison to age-matched LT-Control mice. g, Cardiac fibrosis was also evident in 
LT-Atg5i mice. Representative images of H&E and Massons Trichrome are shown. Scale bars,100 μm. 
h, Age-matched skinned mice. LT-Atg5i mice show kyphosis (yellow dotted line traces the arch of the 
spine). They often displayed premature greying (dotted rectangle). Arrows indicate the presence of 
inflammation. 
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Figure 2:  LT-Atg5i mice present with accelerated aging phenotypes.
a, Extramedullary haematopoiesis is present in the spleens of LT-Atg5i mice in com-
parison to age-matched controls. Scale bars,100 μm. b, Composition of the peripheral 
immune system in LT-Atg5i mice is reminiscent of old control mice. (n=5-6 mice per 
group). c, Six-month-old LT-Atg5i mice (four months dox treatment) displayed 
increased serum levels of IL-6 and TNF (LT-Atg5i n=5, LT-Ctrl n=8; Mann Whitney 
Test). d-h, LT-Atg5i mice display alterations in skeletal muscle after six-months of dox 
treatment. (d) LT-Atg5i mice display a significant difference in minimum feret size (n= 
4 R-Ctrl and 4 R-Atg5i, Mann Whitney test) and (e) cross-sectional area (n= 4 R-Ctrl 
and 4 R-Atg5i, Mann Whitney test). LT-Atg5i mice also display a decrease in Pax7 
nuclear positivity per fibre (f), an increase in central nucleation (g), and positivity for 
the mitochondrial marker TOM20 (h), as determined by tissue immunofluorescence 
(unpaired two-tailed Welches t-test; n= 4 R-Ctrl and 4 R-Atg5i). Error bars indicate 
standard deviations. *p<0.05; **p<0.01, ***p<0.001
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Figure 3:  Autophagy inhibition drives senescence in vivo
a-d, Markers of senescence can also be seen across multiple tissues in our LT-Atg5i 
cohorts treated with dox for four months including in (a) kidney, (b) heart, and (c) liver. (d) 
LT-Atg5i livers stain positively for senescence associated β-galactosidase and p21 unlike 
age-matched control mice (scale bar, 25 μm). e, Six-month doxycycline treated LT-Atg5i 
livers display an increase in the frequency and abundance of γ-H2AX at telomeres, a 
marker associated with increasing chronological age (unpaired two-tailed t-test; n=5). f, A 
representative example image shown. Arrowheads point to TAF that are magnified on the 
right of the image. Scale bar, 10 μm. Error bars indicate standard deviation ***p<0.001
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Figure 4:  Restoration of autophagy partially restores health-span
a, Schematic of R-Atg5i study. Briefly two-month old mice are given dox to induce Atg5 down-
regulation for four months at which point they exhibit ageing-like phenotypes. Dox is then 
removed and autophagy restored. b, Tissues from R-Atg5i mice with autophagy restored for 
two months display evidence of ATG5 protein and autophagy restoration, yet still stain positive-
ly for markers of senescence. c, Atg5i mice on dox for four months and six months display 
increase frailty scores in comparison to controls (ARU, arbitrary units). While R-Atg5i mice 
where autophagy has been restored for four months, display a recovery (Two-way ANOVA with 
Tukey’s correction for all comparisons, n=3-16). d, Whole blood cell counts from R-Atg5i mice 
display no difference in comparison to age matched R-Control mice (unpaired two-tailed t-test; 
n=11 per group). e, Inflammatory serum cytokines IL6 and TNF are equivalent in R-Atg5i and 
R-Control mice two-months post dox removal (Mann Whitney test; n= 3 R-Ctrl and 4 R-Atg5i). 
f, Red blood cell distribution width (RDW) is altered in aged autophagy-restored cohorts (four 
months dox, eight months restoration) (unpaired two-tailed t-test; n=14 per group). Error bars 
indicate standard deviation; NS denotes not significant. *p<0.05; **p<0.01, ***p<0.001.
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Figure 5:  Restoration of autophagy does not reverse markers of ageing
a, p62/Sqstm1 staining of R-Atg5i liver highlights the incomplete removal of aggregates four months after 
autophagy restoration. Scale bars,100 μm. b, The same livers have a higher incidence of age associated 
pigmentation in comparison to age-matched control mice. (yellow arrow). c, TAF frequency and abundance 
also remains elevated in R-Atg5i mice (unpaired two-tailed t-test; n= 4 R-Ctrl and 3 R-Atg5i). d-h, Skeletal 
muscle analysis from four months dox treated and two months restored R-Atg5i mice. R-Atg5i muscle fibres 
continue to display significant alterations in (d) minimum feret size (n= 4 R-Ctrl and 3 R-Atg5i, Mann Whitney 
test) and (e) cross-sectional area (n= 4 R-Ctrl and 3 R-Atg5i, Mann Whitney test), but with a recovery of (f) 
central nucleation. (g) Pax7 nuclear positivity per fibre and (h) positivity for the mitochondrial marker TOM20 
displays a heterogeneous recovery pattern in these mice, as measured by tissue immunofluorescence. (f-h, 
unpaired two-tailed Welches t-test; n= 2 R-Ctrl and 4 R-Atg5i). Error bars indicate standard deviations. 
*p<0.05; **p<0.01, ***p<0.001
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Figure 6:  R-Atg5i mice are associated with accelerated spontaneous tumor develop-
ment
a, R-Atg5i mice on display a reduced lifespan in comparison to R-Control mice (p<0.01). b, 
Increased frequency of spontaneous tumour formation in R-Atg5i cohorts (p<0.001). c, Tumor 
spectrum in R-Atg5i mice versus R-Control mice. d - e, Examples of R-Atg5i tumour histology. 
H&E staining and immunostaining of indicated proteins. Scale bars, 100μm.
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Supplementary Figure 1: Characterisation of LT-Atg5i mice
a, LT-Atg5i mice display no life-span associated sex bias (Red, LT-Atg5i Males; Purple, LT-Atg5i Females; 
p=0.8). b, LT-Atg5i mouse weight plateau while LT-Control mice continue to gain weight over their lifetime. 
c, Example of mouse suffering from ulcerative dermatitis. d, Splenic weights were increased in LT-Atg5i 
mice in comparison to age matched LT-Control mice. e, LT-Atg5i mice also display an increase in liver 
weight. f-h, liver function of LT-Atg5i mice as determined using serum samples. LT-Atg5i mice on dox for 4 
months display (f) an increase in serum ALT and (g) a decrease in serum albumin that is further exacerbated 
in a subset of LT-Atg5i EoL individuals (yellow circles). (h) The only sample tested that displayed an increase 
in serum bilirubin levels was also from a mouse displaying high levels of serum ALT and low levels of serum 
album. Error bars indicate standard deviations. *p<0.05; **p<0.01, ***p<0.001
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Supplementary Figure 2: Kidney alterations in LT-Atg5i mice
(a) LT-cohorts treated with doxycycline for 6 months mice display no significant differences in serum creati-
nine levels (unpaired two-tailed Welches t-test, NS denotes not significant; n= 3 LT-Control and 4 LT-Atg5i). 
At death only a subset of LT-Atg5i mice display an increase in serum creatinine levels. b-f, LT-Atg5i mouse 
kidneys treated with doxycycline for 6 months present with (b) evidence of sclerotic glomeruli determined 
using PAS stain that are also (c-d) enlarged and hypercelluar in comparison to LT-Control (p=0.0479, 
unpaired two-tailed t-test; n= 4 LT-Control and 3 LT-Atg5i, the cross-sectional area of 10 randomly chosen 
glomeruli were measured per mouse). (e) Congo red and (f) P62/Sqstm1 staining of LT-Atg5i mouse 
kidneys treated with doxycycline for 6 months highlights an increase in protein aggregation not present in 
age-matched LT-Control mice. g, Cardiac tissue from LT-Atg5i mice at death was significantly heavier than 
age-matched LT-Control mice. (p=0.0108). Error bars indicate standard deviations. *p<0.05; **p<0.01, 
***p<0.001
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Supplementary Figure 3: Systemic alterations in LT-Atg5i mice
a, LT-Atg5i mice display evidence of widespread immune infiltration across multiple tissues in 
comparison to age-matched controls. Scale bars,100 μm. b, White blood cell counts (WBC) of 
LT-Control and LT-Atg5i mice treated with doxycycline for 4 months (6 months old) (unpaired 
two-tailed Welches t-test, n=5-6 per group). c, Skeletal muscle displays markers of senescence 
in LT-Atg5i cohorts on doxycycline for 4 months. **p<0.01
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Supplementary Figure 4: Hypomorphic LT-Atg5i_2 mice also display aging phenotypes
a-c, LT-Atg5i_2 mice phenotypically recapitulate premature ageing phenotypes including (a) kyphosis, (b) 
increased frailty (ARU, arbitrary units; Mann-whitney n= 14 LT-Control and 5 LT-Atg5i_2 mice), and (c) 
reduced longevity. d-f However, Atg5i_2 mice appear to have a hypomorphic phenotype and do not recapitu-
late the phenotypes found in Atg5 knock-out and LT-Atg5i. These include no evidence of (d) hepatomegaly 
or (e) splenomegaly. (f) Correspondingly, p62/SQSTM1 and LC3 levels do not accumulate to the same 
degree in LT-Atg5_2 mice treated with doxycycline for 6 weeks. Scale bars,100 μm. Error bars indicate 
standard deviations. *p<0.05
Supplementary Figure 4 _ Cassidy
0 100 200 300 400
0
50
100
LT-Atg5i_2
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/528984doi: bioRxiv preprint first posted online Jan. 23, 2019; 
010
20
30
40
b
0
1
2
3
4
R-Atg5iR-Control
Liv
er
 W
eig
ht
 (g
)
4 Months Dox
4 Months Recovery
0
500
1000
1500
AL
T 
(U
/L
)
R-Atg5iR-ControlLT-Control LT-Atg5i
c
6 Months Dox 4 Months Dox
2 Months Recovery
Al
bu
m
in 
(g
/L
)
6 Months Dox
LT-Control LT-Atg5i
4 Months Dox
LT-Control LT-Atg5i R-Control R-Atg5i
4 Months Dox
2 Months Recovery
0.0
0.2
0.4
0.6
R-Control R-Atg5i LT-Control LT-Atg5i
4 Months Dox
4 Months Recovery
8 Months Dox
Sp
len
ic 
W
eig
ht
 (g
)
a
Supplementary Figure 5: Autophagy restoration reverses hepatomegaly and splenomegaly
a, Splenic and b, liver weights from R-Atg5i mice exhibit evidence of recovery. c, In addition R-Atg5i 
mice display a reduction in serum ALT levels (unpaired two-tailed Welches t-test; n= 3-4 per cohort). d-f, 
R-Atg5i mice 4 months post dox removal display evidence of recovery in the kidneys as determined by 
(d-e) normalisation of glomeruli size appeared relative to age-matched controls (unpaired two-tailed 
Mann whitney, n=3-4 mice per group) and (f) the absence of sclerosis. g, A partial recovery in serum 
albumin levels is also present in these mice unpaired two-tailed Welches t-test; n= 2-9 per cohort). Error 
bars indicate standard deviations. *p<0.05; **p<0.01, ***p<0.001
p=0.0053
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Supplementary Figure 6: Autophagy restoration displays segmental rescue of tissue pheno-
types
a-b, Skeletal muscle displays no rescue of phenotype once Atg5i mice are removed from dox. As 
determined by (a) minimal feret size, and (b) cross-sectional area. (unpaired two-tailed Welches t-test, 
n=3-5 per group). c, Cardiac fibrosis was still present in R-Atg5i mice 4 months post dox removal. Error 
bars indicate standard deviations. *p<0.05
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